mRNA |
ruxolitinib |
CTRPv2 |
pan-cancer |
AAC |
-0.095 |
0.01 |
mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.01 |
mRNA |
PLX4720 |
CCLE |
pan-cancer |
AAC |
0.11 |
0.01 |
mRNA |
BRD-K63431240 |
CTRPv2 |
pan-cancer |
AAC |
-0.093 |
0.02 |
mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.085 |
0.02 |
mRNA |
LY317615 |
GDSC1000 |
pan-cancer |
AAC |
-0.083 |
0.02 |
mRNA |
GSK-J4 |
CTRPv2 |
pan-cancer |
AAC |
0.27 |
0.02 |
mRNA |
dabrafenib |
GDSC1000 |
pan-cancer |
AAC |
0.074 |
0.02 |
mRNA |
GSK461364 |
CTRPv2 |
pan-cancer |
AAC |
-0.081 |
0.02 |
mRNA |
PF-562271 |
GDSC1000 |
pan-cancer |
AAC |
-0.081 |
0.02 |